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Abstract. Previous studies have detected a higher level of
ferritin in patients with hepatocellular carcinoma (HCC), but
a potential causal association between serum ferritin level
and hepatocarcinogenesis remains to be clarified. Using
a well‑established prospective cohort and longitudinally
collected serial blood samples, the association between
baseline ferritin levels and HCC risk were evaluated in
1,152 patients infected with hepatitis B virus (HBV), a major
risk factor for HCC. The association was assessed by Cox
proportional hazards regression model using univariate
and multivariate analyses and longitudinal analysis. It was
demonstrated that HBV patients who developed HCC had
a significantly higher baseline ferritin level than those who
remained cancer‑free (188.00 vs. 108.00 ng/ml, P<0.0001).
The patients with a high ferritin level (≥200 ng/ml) had
2.43‑fold increased risk of HCC compared to those with
lower ferritin levels [hazard ratio (HR), 2.43; 95% confidence
interval, 1.63‑3.63]. A significant trend of increasing HRs
along with elevated ferritin levels was observed (P for trend
<0.0001). The association was still significant after multivariate adjustment. Incorporating ferritin into the α‑fetoprotein
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(AFP) model significantly improved the performance of
HCC prediction (the area under the curve from 0.74 to 0.77,
P=0.003). Longitudinal analysis showed that the average
ferritin level in HBV patients who developed HCC was
persistently higher than in those who were cancer‑free during
follow‑up. HCC risk reached a peak at approximately the
fifth year after baseline ferritin detection. Moreover, stratified analyses showed that the association was noted in both
males and females, and was prominent in patients with a low
AFP value. In short, serum ferritin level could independently
predict the risk of HBV‑related HCC and may have a complementary role in AFP‑based HCC diagnosis. Future studies
are warranted to validate these findings and test its clinical
applicability in HCC prevention and management.
Introduction
Hepatocellular carcinoma (HCC) is the third leading cause
of cancer‑related death worldwide and a major cause of death
in patients with cirrhosis (1). By the time HCC is detected,
it has often reached an advanced stage for which there is no
curative treatment. In order to identify HCC earlier, efforts
have focused on patients with chronic hepatitis B virus (HBV)
infection, which affects 350 million persons worldwide and
is the most common risk factor for HCC (1). The ability to
identify patients who are at high risk for HBV‑related HCC
would benefit the prevention and early detection of HCC.
Recent studies have indicated that measurement of
ferritin, the major cellular storage protein for iron (2), may
allow for such early detection of HCC. In vitro studies showed
that iron induced increased ferritin synthesis by hepatoma
cell lines and enhanced tumor cell growth (3,4). Elevated
serum ferritin was also associated with inflammation and
liver diseases (2,5,6). Moreover, ferritin that is synthesized
by tumor cells may exert adverse effects on host immune
responses and defense mechanisms (3). Population studies
have clearly documented that HCC patients have a higher
level of ferritin than healthy subjects or patients with other
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liver diseases (7‑9), but retrospective studies cannot clarify
whether the increased level is the cause or consequence of
HCC because ferritin is also produced by the tumor cells.
Meanwhile, very few studies have prospectively evaluated
the relationship between serum ferritin level and HCC risk in
HBV patients. A nested case‑control study in Taiwan reported
that 192 men who developed primary HCC and/or died of
cancer had higher mean serum ferritin at the start of the study,
compared to those who were alive and free of HCC at the
date the case failed (developed HCC or died of cancer) (10). A
study conducted in Korean patients with chronic hepatitis B
and cirrhosis reported that males with sustained high serum
ferritin levels had a high chance of developing HCC (5);
however, in this study, only 162 patients (46 females) were
included, ferritin levels were merely measured within the
first 8 months, and covariates were not considered. We
designed a prospective cohort study with more than 10‑year
follow‑up and longitudinally collected serial blood samples
from HBV‑infected patients in order to further clarify the
association between baseline ferritin levels and HCC risk in
HBV‑infected patients, and to explore the dynamic change of
ferritin level and HCC risk over time.
Subjects and methods
Subjects. The subjects were identified from an ongoing
clinic‑based patient cohort that was established in 1988 (11).
The patients were recruited when they visited the Liver
Disease Prevention Center at Thomas Jefferson University
Hospital for the treatment of chronic HBV or HCV infection and liver diseases including cirrhosis, fibrosis, and/or
HCC. There was no restriction on age, gender, and disease
etiology for patient recruitment. Majority (>90%) of the
patients in the cohort were of Korean ancestry. The patients
included in the current study met the following criteria: i) To
eliminate the confounding effects from disease etiologies,
patients had HBV infection only, without concomitant infection with HCV, HIV, or other viruses; ii) to minimize the
confounding effects of population stratification and ethnic
origin, patients were Korean Americans; iii) patients had
developed primary rather than secondary HCC during
follow‑up; iv) patients were followed for at least 1 year, and
during which time HCC did not develop; v) patients had both
ferritin and α‑fetoprotein (AFP) values measured simultaneously at study entry; and vi) major demographic and clinical
data were available, such as date of HCC diagnosis. This
study was approved by the Institutional Review Board of
Thomas Jefferson University. Written informed consent was
obtained from each patient.
Data collection. Demographic and clinical data were obtained
by reviewing medical charts and/or consulting the treating
physicians. Related variables included age, gender, ethnicity,
smoking status, drinking status, cirrhosis status, and family
history of cancer. Ever smokers and drinkers were defined as
previously (12). Liver cirrhosis and HCC were diagnosed by
the combination of clinical diagnosis and imaging techniques
(e.g., ultrasound, computed tomography, magnetic resonance
imaging), complemented by blood markers (e.g., AFP) (11).
Ferritin levels for each patient were detected at the initial visit,

as well as at follow‑up visits, with the intervals determined by
the treating physicians.
Statistical analysis. SAS (version 9.4; SAS Institute, Inc.,
Cary, NC, USA) and Stata (version 12.0; StataCorp LP,
College Station, TX, USA) software packages were used
for data analyses. All statistical tests were two‑sided, and
a P‑value of less than 0.05 was considered as the threshold
of statistical significance. The clinical endpoint analyzed in
this study was HCC development. Time to HCC development
was defined as the date from the study entry to the date of
HCC diagnosis or last follow‑up. Patients who were free of
HCC at the last follow‑up date were censored for analysis.
The patients were then divided into two, three, or four risk
groups, according to the clinical cut‑off of 200 ng/ml (2,13),
or median/tertile/quartile of ferritin level in cancer‑free
HBV patients. The cumulative incidence of HCC in each risk
group was plotted using the Nelson‑Aalen method (14) and
compared using the log‑rank test. The association between
ferritin level and HCC risk was evaluated using univariate
and multivariate Cox proportional hazards regression model,
adjusting for age, gender, smoking status, drinking status,
cirrhosis, and family history of cancer. Because all patients
received standard‑of‑care treatment based on the AASLD
guidelines and adjustment of treatment did not affect the
results, we did not include treatment in the multivariate
adjustment in the current study. The proportional hazards
assumption was validated using the test based on Schoenfeld
residuals. The significance and strength of association
was presented as hazard ratio (HR) with 95% confidence
interval (CI). Discrimination accuracy for predicting the
development of HCC was evaluated by constructing receiver
operating characteristic (ROC) curves and calculating the
area under the curve (AUC). Interactions between ferritin
levels and other variables on HCC risk were assessed by
adding an interaction term into the Cox regression model.
Time‑dependent effect of ferritin levels on HCC risk was
analyzed using the flexible parametric survival model with
a restricted cubic spline function (15). To better understand
the dynamic change of ferritin during follow‑up, we selected
a sub‑cohort of 461 patients whose ferritin level was detected
≥3 times since the initial visit. The longitudinal trends of
temporal changes in average ferritin levels were plotted by
fitting a smoothing spline over time and compared between
the patients who developed HCC and those who remained
cancer‑free during follow‑up (16).
Results
Patient characteristics. A total of 1,152 HBV patients were
included in this study, and among them, 96 (8.3%) patients
developed early‑stage HCC during follow‑up. The patient
characteristics are summarized in Table I. The mean age
of patients at enrollment was 43.6 years old (age range:
18.7‑77.8 years). The majority of patients were males (66.1%,
sex ratio: 1.95), never smokers (59.7%), never drinkers (56.1%),
without cirrhosis (71.8%) or a family history of cancer (67.4%).
As expected, HCC risk was significantly increased among
older patients (HR=2.23, 95% CI, 1.36‑3.65), males (HR=1.88,
95% CI, 1.01‑3.47), ever smokers (HR=2.47, 95% CI, 1.39‑4.38),
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Table I. Characteristics of the study population.
Univariate analysis
Multivariate analysisa
	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Total HBV
HBV patients who
HR		
HR
Variables
patients, no. (%) developed HCC, no. (%)
(95% CI)
P‑value
(95% CI)
P‑value
Age (years),
43.61 (11.75)
50.97 (10.36)
1.07 (1.05‑1.08) <0.0001c
1.05 (1.03‑1.07) <0.0001c
mean (SD)
<43
550 (47.7)
22 (22.9)
1.00		
1.00
≥43
602 (52.3)
74 (77.1)
3.48 (2.16‑5.61) <0.0001c
2.23 (1.36‑3.65)
0.0014c
Gender						
Female
391 (33.9)
15 (15.6)
1.00		
1.00
Male
761 (66.1)
81 (84.4)
2.81 (1.62‑4.88)
0.0002c
1.88 (1.01‑3.47)
0.0450c
Smoking status						
Never
688 (59.7)
35 (36.5)
1.00		
1.00
c
Ever
382 (33.2)
49 (51.0)
2.61 (1.69‑4.03) <0.0001
2.47 (1.39‑4.38)
0.0021c
Unknown
82 (7.1)
12 (12.5)
2.84 (1.47‑5.47)
0.0019 12.43 (2.92‑52.97) 0.0007
Drinking status						
Never
646 (56.1)
41 (42.7)
1.00		
1.00
Ever
425 (36.9)
45 (46.9)
1.72 (1.12‑2.62)
0.0123c
0.67 (0.38‑1.16)
0.1527
Unknown
81 (7.0)
10 (10.4)
1.90 (0.95‑3.79)
0.0693
0.15 (0.03‑0.71)
0.0171
Cirrhosis						
No
827 (71.8)
19 (19.8)
1.00		
1.00
c
Yes
325 (28.2)
77 (80.2)
12.25 (7.41‑20.25) <0.0001
7.62 (4.53‑12.83) <0.0001c
Family history
of cancer
No
776 (67.4)
57 (59.4)
1.00		
1.00
Yes
376 (32.6)
39 (40.6)
1.50 (1.00‑2.25)
0.0523
1.21 (0.80‑1.84)
0.3657
b
b,c
b
AFP (ng/ml),
3.10 (2.00‑6.40)
10.86 (5.15‑47.05)
1.62 (1.50‑1.76) <0.0001
1.51 (1.36‑1.67) <0.0001b,c
median (IQR)
<20
1015 (88.1)
59 (61.5)
1.00		
1.00
≥20
137 (11.9)
37 (38.5)
5.39 (3.57‑8.13) <0.0001c
2.75 (1.78‑4.25) <0.0001c
HCC, hepatocellular carcinoma; SD, standard deviation; IQR, interquartile range; AFP, α‑fetoprotein; HR, hazard ratio; CI, confidence interval.
a
Adjusted for age, gender, smoking status, drinking status, family history of cancer, and cirrhosis, where appropriate. bAfter natural log transformation. cP<0.05.

cirrhotic patients (HR=7.62, 95% CI, 4.53‑12.83), and patients
with a high AFP value (HR=2.75, 95% CI, 1.78‑4.25). Although
increased HCC risk was observed in ever drinkers and patients
with a family history of cancer in the univariate analyses, the
associations were not statistically significant after adjustment
for covariates.
Association between ferritin level and HCC risk. HBV
patients who developed HCC had a significantly higher
ferritin level [median 188.00 ng/ml, interquartile range (IQR)
119.50‑299.76 ng/ml] than those who remained cancer‑free
(median 108.00 ng/ml, IQR 53.10‑204.95 ng/ml, P<0.0001). We
then divided HBV patients into different risk groups according
to the clinical cut‑off or percentile cut‑offs. As shown in
Fig. 1, the cumulative HCC incidence was significantly higher
in patients with a high ferritin level than in those with a low
ferritin level, no matter which kind of cut‑offs were used (all
log‑rank P<0.0001). Compared to the patients with a ferritin

level less than 200 ng/ml, the patients with a high ferritin level
(≥200 ng/ml) had 2.43‑fold increased risk of HCC (HR=2.43,
95% CI, 1.63‑3.63, Table II). The association was still significant
after adjusting for age, gender, smoking status, drinking status,
and family history of cancer (HR=1.76, 95% CI, 1.16‑2.65)
and became borderline significant when cirrhosis and AFP
were further added to multivariate adjustment (HR=1.45,
95% CI, 0.96‑2.19). When patients were categorized according
to median/tertile/quartile cutoffs, the association between
ferritin and HCC risk was consistently observed in univariate
and multivariate analyses (Table II). Moreover, a trend of
increasing HRs along with elevated ferritin levels was noted
(P for trend <0.0001 in univariate analyses and <0.01 after
multivariate adjustment, Table II).
Prediction performance of ferritin combined with AFP.
AFP is a commonly used tumor marker in HCC diagnosis,
although with a non‑optimal discrimination accuracy (17). We
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Figure 1. Cumulative incidence of HBV‑related HCC. The cumulative incidence of HCC was plotted using the Nelson‑Aalen method by analyzing Ferritin as a
categorical variable by clinical cut‑off of (A) 200 ng/ml, (B) median, (C) tertile, and (D) quartile cut‑offs. HBV, hepatitis B virus; HCC, hepatocellular carcinoma.

then investigated whether incorporating ferritin into the AFP
prediction model could improve the performance of predicting
HCC. The results showed that compared to the performance
in the model with AFP values, the prediction performance
significantly increased in the model in combination of ferritin
and AFP levels (AUC from 0.74 to 0.77, P=0.003; Fig. 2).
Time‑dependent effect and dynamic change of ferritin level.
Time‑dependent effect of ferritin level on HCC risk was
assessed using the flexible parametric model. As shown in
Fig. 3A, after the initial visit, HCC risk significantly increased
in the first 5 years, reached a peak at approximately the fifth
year, and kept stable after 10 years. To evaluate dynamic
change of ferritin, we also selected a sub‑cohort of 461 patients
with 4309 detections of ferritin at both baseline and follow‑up
visits, and depicted the longitudinal trend of average ferritin
values by fitting a smoothing spline over time (Fig. 3B).
The average ferritin level in HBV patients who developed
HCC (n=50) was persistently higher than in those remaining
cancer‑free (n=411).
Stratified and joint effects of ferritin level on HCC risk. We
stratified the main effect analysis according to patients' characteristics. In the univariate analyses, the association of ferritin
level with HCC risk was significant in both strata divided by
age, gender, drinking status, and family history of cancer, and
only evident in ever smokers (P=0.0233), non‑cirrhotic patients

Figure 2. Receiver operating characteristic curves for assessment of prediction performance of HCC. The AUC was compared between the AFP models
without and with ferritin levels. AUC, area under the curve; HCC, hepatocellular carcinoma.

(P=0.0155), and patients with a AFP value less than 20 ng/ml
(P=0.0004; Table III). After multivariate adjustment, we only
observed a borderline significant association in older patients
(P=0.0940) and patients with a low AFP value (P=0.0837).

HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval. aAdjusted for age, gender, smoking status, drinking status, and family history of cancer. bAdjusted for age, gender, smoking status,
drinking status, family history of cancer, and cirrhosis. cAdjusted for age, gender, smoking status, drinking status, family history of cancer, cirrhosis, and AFP level. dP<0.05.

log transformed
96/1152		
1.77 (1.47‑2.14)
<0.0001d
1.55 (1.25‑1.92)
<0.0001d
1.42 (1.16‑1.74)
0.0008d
1.39 (1.14‑1.70)
0.0011d
By clinical cut‑off									
<200 ng/ml
51/832
<0.0001d
1.00		
1.00		
1.00		
1.00
d
d
≥200 ng/ml
45/320		
2.43 (1.63‑3.63)
<0.0001
1.76 (1.16‑2.65)
0.0074
1.44 (0.95‑2.17)
0.0848
1.45 (0.96‑2.19)
0.0748
By median							
<Median
19/548
<0.0001d
1.00		
1.00		
1.00		
1.00
≥Median
77/604		
3.92 (2.37‑6.48)
<0.0001d
2.59 (1.54‑4.35)
0.0003d
2.41 (1.43‑4.06)
0.0009d
2.30 (1.37‑3.88)
0.0017d
By tertile
1st tertile
9/361
<0.0001d
1.00		
1.00		
1.00		
1.00
2nd tertile
34/387		
3.72 (1.78‑7.76)
0.0005d
2.38 (1.12‑5.03)
0.0239d
3.04 (1.44‑6.42)
0.0036d
2.95 (1.39‑6.28)
0.0050d
d
d
d
3rd tertile
53/404		
5.66 (2.79‑11.48)
<0.0001
3.11 (1.50‑6.47)
0.0023
3.02 (1.47‑6.20)
0.0026
3.00 (1.46‑6.16)
0.0027d
Ptrend				
<0.0001d		 0.0021d		0.0070d		0.0066d
By quartile						
1st quartile
5/269
<0.0001d
1.00		
1.00		
1.00		
1.00		
2nd quartile
14/279		
2.82 (1.02‑7.83)
0.0465d
1.86 (0.66‑5.20)
0.2394
2.36 (0.84‑6.67)
0.1042
2.57 (0.91‑7.26)
0.0757
3rd quartile
32/295		
6.26 (2.44‑16.08)
0.0001d
3.40 (1.30‑8.91)
0.0127d
4.23 (1.62‑11.07)
0.0033d
4.13 (1.57‑10.87)
0.0040d
4th quartile
45/309		
8.70 (3.45‑21.91)
<0.0001d
4.45 (1.73‑11.48)
0.0020d
4.18 (1.63‑10.71)
0.0029d
4.24 (1.66‑10.84)
0.0026d
Ptrend				
<0.0001d		<0.0001d		0.0010d		0.0012d

Univariate analysis
Multivariate analysisa
Multivariate analysisb
Multivariate analysisc
	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
HCC/total
Log‑rank
HR		HR		HR		HR
Ferritin values
patients (n)
P‑value
(95% CI)
P‑value
(95% CI)
P‑value
(95% CI)
P‑value
(95% CI)
P‑value

Table II. Associations between Ferritin level and HCC risk.
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Figure 3. Time‑dependent effect and dynamic change of Ferritin level. (A) Time‑dependent effect of Ferritin level on HCC risk, red solid line represents HR,
shaded area shows 95% confidence interval, blue dash line indicates a reference HR of 1; (B) Longitudinal trend of average Ferritin level in the patients who
developed HCC (red solid line) and those who were cancer‑free (blue dash line), grey lines indicate individual profiles for all subjects. HR, hazard ratio; HCC,
hepatocellular carcinoma.

Because the clinical normal range differed between
females and males (13) and because we detected a joint
effect between ferritin level and gender on HCC risk (P for
interaction= 0.0087), we further evaluated gender‑specific
effect and compared the cumulative incidence in females
and males. As expected, ferritin levels were much higher in
males than in females (median 160 ng/ml vs. 50.40 ng/ml,
P<0.0001). Both female and male HBV patients who developed HCC had significantly higher ferritin levels compared
to those who were still cancer‑free (134 vs. 48.95 ng/ml,
P=0.0003 in females; 188.90 vs. 154.80 ng/ml, P=0.0025 in
males, Table IV). The significantly increased cumulative incidence was observed in both female and male patients with a
high ferritin level when gender‑specific clinical cut‑offs were
used (Fig. 4A and B).
We also detected a joint effect between ferritin and
AFP level on HCC risk (P for interaction=0.0036). We then
compared ferritin level and cumulative incidence in patients
with a low or high AFP value. We noticed that in patients
with a low AFP value (<20 ng/ml), the HBV patients who
developed HCC had a significantly higher level of ferritin
than those who remained cancer‑free (178 vs. 103.25 ng/ml,
P<0.0001; Table V); however, in patients with a high AFP value
(≥20 ng/ml), the ferritin level in the HCC patients was slightly
lower than that in the non‑HCC patients (230 vs. 283 ng/ml),
but the difference was not statistically significant. Similarly,
significantly increased cumulative incidence of HCC with
elevated ferritin level was observed in patients with a low AFP
value (Fig. 4C and D).
Discussion
Serum ferritin is a widely available and easily measured
biochemical parameter in clinics. Previous studies detected a
higher level of ferritin in HCC patients; however, these studies
did not reveal whether there was a causal association between
serum ferritin level and hepatocarcinogenesis in HBV infected
patients. In the current study based on a well‑established

prospective cohort, we demonstrated that baseline ferritin
level could independently predict the risk of HBV‑related
HCC, especially in the first 10 years of follow‑up. Moreover,
the association between ferritin level and HCC risk was noted
in both males and females, and was prominent in patients with
a low AFP value.
The tumor enhancing effect of iron has been well documented (18,19). Accumulating evidence has indicated that an
increased iron level predisposes a patient to infection, induces
oxidative stress, modifies the immune system, and facilitates
the growth of tumor cells (2,5,20,21). Furthermore, antitumor effect of iron depletion by deferoxamine was observed
in nude mice bearing human HCC (22). As an iron storage
protein, ferritin makes iron available for critical cellular
processes while protecting lipids, DNA, and proteins from
the potentially toxic effects of iron (23). Serum ferritin is an
inexpensive biomarker in identifying clinically significant
iron overload (23). Elevated ferritin concentrations could
also be observed in inflammatory processes, autoimmune
diseases, neurodegenerative, metabolic syndrome, and malignant diseases (23). In addition to the amount synthesized by
tumor cells, ferritin is also released into the circulation by
damaged hepatocytes in liver diseases. Cirrhosis is almost
always present when HCC is diagnosed and progressive
hepatic iron loading develops in one‑third of patients with
long‑standing liver cirrhosis (21); however, previous studies
failed to clarify whether ferritin is an independent predictor
of HCC or acts indirectly through coexisting cirrhosis.
A recent animal model of dietary iron overload reported
iron‑free preneoplastic nodules and HCC developed in the
absence of fibrosis or cirrhosis, suggesting that ionic iron
may also be directly hepatocarcinogenic (24,25). In the
current study, which was conducted in chronic HBV infected
patients, we demonstrated the association between ferritin
and HCC risk that was independent of other liver diseases
including cirrhosis (Table II).
It is well known that the average ferritin level in males is
much higher than in females, thus a gender‑specific cut‑off is
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Table III. Associations between Ferritin level and HCC risk stratified by patients' characteristics.

Variable

Ferritin values
(ng/ml)

HCC/total
patients (N)

Univariate analysis
Multivariate analysisa
‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
HR (95% CI)
P‑value
HR (95% CI)
P‑value

Age (years)						
<43
<200
12/416
1		
1
≥200
10/134
2.74 (1.18‑6.33)
0.0188b
1.70 (0.70‑4.17)
0.2430
≥43
<200
39/416
1		
1
≥200
35/186
2.11 (1.34‑3.33)
0.0013b
1.50 (0.93‑2.40)
0.0940
P for interaction				
0.6144		
0.9970
Gender						
Female
<200
9/353
1		
1
≥200
6/38
7.29 (2.59‑20.51)
0.0002b
1.25 (0.29‑5.45)
0.7695
Male
<200
42/479
1		
1
≥200
39/282
1.64 (1.06‑2.53)
0.0269b
1.45 (0.93‑2.27)
0.1040
b
P for interaction				
0.0087 		0.9203
Smoking status						
Never
<200
23/533
1		
1
≥200
12/155
1.88 (0.94‑3.78)
0.0758
1.12 (0.54‑2.33)
0.7679
Ever
<200
23/236
1		
1
≥200
26/146
1.92 (1.09‑3.36)
0.0233b
1.48 (0.81‑2.71)
0.2064
P for interaction				
0.9982		
0.5633
Drinking status						
Never
<200
26/505
1		
1
≥200
15/141
2.23 (1.18‑4.21)
0.0136b
1.14 (0.58‑2.24)
0.7121
Ever
<200
21/264
1		
1
≥200
24/161
1.93 (1.08‑3.47)
0.0275b
1.41 (0.76‑2.64)
0.2774
P for interaction				
0.7706		
0.8010
Cirrhosis						
No
<200
10/639
1		
1
≥200
9/196
3.04 (1.24‑7.49)
0.0155b
1.27 (0.46‑3.52)
0.6515
Yes
<200
41/193
1		
1
≥200
36/124
1.43 (0.91‑2.24)
0.1176
1.27 (0.80‑2.03)
0.3078
P for interaction				
0.1410		
0.5747
Family history of cancer						
No
<200
30/575
1		
1
≥200
27/201
2.70 (1.61‑4.54)
0.0002b
1.53 (0.89‑2.65)
0.1263
Yes
<200
21/257
1		
1
≥200
18/119
1.95 (1.04‑3.67)
0.0375b
1.25 (0.63‑2.49)
0.5233
P for interaction				
0.4255		
0.8123
AFP (ng/ml)						
<20
<200
34/778
1		
1
≥200
25/237
2.55 (1.52‑4.28)
0.0004b
1.61 (0.94‑2.77)
0.0837
≥20
<200
17/54
1		
1
≥200
20/83
0.72 (0.38‑1.38)
0.3194
0.75 (0.38‑1.46)
0.3954
b
P for interaction				
0.0036 		0.0583b
HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; AFP, α‑fetoprotein. aAdjusted for age, gender, smoking status,
drinking status, family history of cancer, cirrhosis, and AFP level, where appropriate. bP<0.05.

often suggested in clinics (2,13,26). A recent study reported
an independent predicting value of serum ferritin in the

development of HCV‑related HCC, and this association
was only observed in male patients (27). Previous studies
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Table IV. Ferritin levels by gender.

Females (n=391)
Males (n=761)
	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Variables
Non‑HCC (n=376)
HCC (n=15)
P‑value
Non‑HCC (n=680)
HCC (n=81)
P‑value
Ferritin (ng/ml),
median (IQR)

48.95
(25.60‑96.95)

134.00
0.0003a
(96.00‑446.00)		

154.80
(95.00‑256.35)

188.90
(124.00‑296.52)

0.0025a

HCC, hepatocellular carcinoma; IQR, interquartile range. aP<0.05.

Table V. Ferritin levels by AFP level.
AFP <20 ng/ml (n=1,015)
AFP ≥20 ng/ml (n=137)
	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Variables
Non‑HCC (n=956)
HCC (n=59)
P‑value
Non‑HCC (n=100)
HCC (n=37)
P‑value
Ferritin (ng/ml),
median (IQR)

103.25
(50.00‑187.25)

178.00
<0.0001a
(119.00‑253.30)		

283.00
(123.20‑619.00)

230.00
(120.00‑495.00)

0.38750a

AFP, α‑fetoprotein; HCC, hepatocellular carcinoma; IQR, interquartile range. aP<0.05.

Figure 4. Cumulative incidence of HBV‑related HCC stratified by gender and AFP value. The cumulative incidence of HCC was compared between patients
with a low and high Ferritin level in (A) females, (B) males, (C) patients with a low AFP value, or (D) patients with a high AFP value. HBV, hepatitis B virus;
HCC, hepatocellular carcinoma.

conducted in HBV patients also identified increased HCC
risk in male patients with a high level of ferritin. But these
studies were either conducted in males alone (10) or involved

a small number of female patients (5). Our present study with
761 males and 391 females demonstrated that the association
between ferritin level and HCC risk was observed in both

ONCOLOGY LETTERS 16: 3499-3508, 2018

males and females, even when males or females were stratified into different risk groups by a gender‑specific cut‑off of
ferritin (Fig. 3). It is unclear whether the inconsistent finding
of ferritin effect on HBV patients compared to HCV patients
signifies that hepatocarcinogenesis differs in patients with
different disease etiologies. It would be worthwhile to
conduct additional studies to validate our finding and clarify
gender‑specific effects.
AFP is a widely recognized tumor marker for the diagnosis
of HCC. However, there have been false‑positive results for
HCC detection, as elevated AFP also occurs in chronic liver
disease and other malignancies than HCC; false‑negative
results were reported as well, as not all HCCs secrete
AFP (17,28,29). Our results showed that the performance of
HCC prediction significantly improved after incorporating
ferritin into the AFP prediction model (Fig. 2), suggesting a
complementary role of ferritin in prediction of HCC development. Adult hepatocytes re‑express AFP mainly through
mechanisms including hepatocyte regeneration, and oxidative
stress induced DNA damage (30). Noritake et al (31) reported
that iron reduction by therapeutic phlebotomy could reduce
the serum AFP in HCV patients, which probably mediated by
the amelioration of enhanced hepatic iron‑mediated oxidative
stress. Although the biological mechanisms underlying the
combined effect of AFP and Ferritin on HCC development are
still needed to be further investigated, the present findings in
our study demonstrated the potential of using these two serum
markers for the joint diagnosis of HCC. Nevertheless, it should
be noted that after adding ferritin to the model, the diagnostic
power was still moderate, albeit slightly increased. Therefore,
it would be worthwhile to study whether a model including
more risk factors, as well as novel molecular markers could
further improve the diagnostic performance. In addition, in the
stratification analyses, we found that the association of ferritin
level with HCC risk was more evident in patients with a AFP
value less than 20 ng/ml. Our result was consistent with the
finding of Zhou et al (32) who suggested that serum ferritin
estimation may be helpful in detection of HCC without elevated
AFP, and further supported the complementary information
from ferritin to AFP‑based HCC diagnosis. Nevertheless, due
to decreased sample size in each stratum, especially in the
patients with a high level of AFP, it should be cautious when
we explained the detected interaction between ferritin and
AFP, as well as, the failure in identifying significant difference
in ferritin levels between HCC and non‑HCC patients when
the comparison was conducted in those with elevated AFP.
Our study was based on a large‑scale and homogenous
cohort of Korean patients with chronic HBV infection, so the
confounding effects of patient ethnicity and disease etiology
have been eliminated. We only included patients who were
followed for at least 1 year, and during which time HCC did not
develop (1‑year exclusion window). This criterion ensured that
all of the patients were free of HCC at study entry. Therefore,
the increased baseline ferritin level was more likely linked to
the development of HCC rather than the release from existing
tumor cells. In order to minimize the confounding effect of
any patient who had undiagnosed HCC at baseline sample
collection, we further restricted the analyses to a sub‑cohort of
patients with a 2‑year exclusion window, that is, only included
the patients who were followed for at least 2 years and had
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not developed HCC within these 2 years. The result from this
sub‑cohort analysis (HR=2.76, 95% CI, 1.60‑4.78; adjusted
HR=2.23, 95% CI, 1.25‑3.97) was very similar to that from
the analysis based on the population with 1‑year exclusion
window (HR=2.43, 95% CI, 1.63‑3.63; adjusted HR=1.76,
95% CI, 1.16‑2.65, Table II), which substantiates the robustness of our findings. Furthermore, ferritin is a non‑invasive,
cost‑effective, and easily obtained biomarker in clinics so that
it can be real‑time detected and repetitively monitored during
follow‑up.
Our study also has limitations. First, liver biopsy is the
gold standard for quantifying iron, while serum ferritin
levels do not always accurately reflect tissue iron (2,23,33).
However, in the current study, very few patients had baseline
serum iron concentration or transferrin saturation, and none
of the patients had detection of tissue iron, so we are unable
to accurately assess the relationship between ferritin, iron,
and the development of HBV‑related HCC. Second, some
important covariates, such as HBV DNA loading and body
mass index, which were reported to be associated with HCC
risk and/or correlate with serum ferritin level (12,34), were not
included in multivariate analyses due to a high percentage of
missing values. Future studies with more complete data could
be designed to evaluate the confounding effects from these
covariates. Third, this study was based on the data collected
in a single institute. Prospective studies from independent
external cohorts are required to validate our results. Moreover,
the generalizability of our findings to patients of other ethnicities or disease etiologies is required to be assessed.
In short, our large scale cohort study indicated that serum
ferritin could prospectively predict hepatocarcinogenesis in
chronic HBV infected patients. Given ferritin is a non‑invasive
blood‑born maker which can be easily obtained from routine
laboratory test and be real‑time monitored during follow‑up,
the clinical significance of ferritin in early diagnosis and effective management of HCC should not be overlooked.
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